Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B. Chalandon Y, et al. Among authors: roosnek e. Biol Blood Marrow Transplant. 2006 Jan;12(1):102-10. doi: 10.1016/j.bbmt.2005.09.010. Biol Blood Marrow Transplant. 2006. PMID: 16399574 Free article. Clinical Trial.
Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
Simonetta F, Masouridi-Levrat S, Beauverd Y, Tsopra O, Tirefort Y, Koutsi A, Stephan C, Polchlopek-Blasiak K, Pradier A, Dantin C, Ansari M, Roosnek E, Chalandon Y. Simonetta F, et al. Among authors: roosnek e. Leuk Lymphoma. 2018 Mar;59(3):590-600. doi: 10.1080/10428194.2017.1344844. Epub 2017 Jul 6. Leuk Lymphoma. 2018. PMID: 28679328
Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back.
Verholen F, Terrettaz M, Roosnek E, Passweg JR, Chalandon Y. Verholen F, et al. Among authors: roosnek e. Eur J Haematol. 2009 Sep;83(3):273-5. doi: 10.1111/j.1600-0609.2009.01282.x. Epub 2009 Jun 2. Eur J Haematol. 2009. PMID: 19500136 No abstract available.
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.
Mohty B, Bel M, Vukicevic M, Nagy M, Levrat E, Meier S, Grillet S, Combescure C, Kaiser L, Chalandon Y, Passweg J, Siegrist CA, Roosnek E; Blood and Marrow Transplant Program; Geneva University Hospitals H1N1 study group. Mohty B, et al. Among authors: roosnek e. Haematologica. 2011 Jun;96(6):896-904. doi: 10.3324/haematol.2011.040386. Epub 2011 Mar 21. Haematologica. 2011. PMID: 21422117 Free PMC article. Clinical Trial.
151 results